Return to homepagePandemic Pact

DEVELOPMENT OF A DRUG CANDIDATE AGAINST CHIKUNGUNYA VIRUS

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93023C00002-P00001-9999-1

Grant search

Key facts

  • Disease

    Chikungunya haemorrhagic fever

  • Start & end year

    2022
    2024

  • Known Financial Commitments (USD)

    $4,696,352

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    DANIEL STREBLOW

  • Research Location

    United States of America

  • Lead Research Institution

    OREGON HEALTH & SCIENCE UNIVERSITY

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

To support the advanced development of a promising candidate therapeutic for viruses with pandemic potential. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.